Shares of Pressure Biosciences (NASDAQ: PBIO) are on the rise this afternoon, up nearly 8% in to $4.90. Pressure Biosciences is an early-stage company focused on the development of novel, enabling technology called Pressure Cycling Technology (PCT).

The company’s various products are gaining recognition in the healthcare sector for its diagnostic equipment such as its newest product, the ProteoSolve Kit, and the Barocycler NEP2320, the Barocycler NEP 3229 and PULSE Tubes, as well as 13 U.S. patents and four foreign patents that cover a various applications of PCT.

Each of these products are designed for the life sciences field for further study in genomics and pretoeomic sample preparation, pathogen inactivation, control of enzymes, immunodiagnostics and protein purification.

Pressure Biosciences recently received a Strong Speculative Buy Rating by Dutton Associates, and was spotlighted by scientists at the New York University (NYU) School of Medicine. The university announced that their use of the company’s patent-pending ProteoSolve LRS was largely responsible for the identification of potential biomarkers in breast and colon cancer tissue.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board